Kuros Biosciences
OverviewSuggest Edit
Kuros Biosciences engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The Сompany's synthetic orthobiologics pipeline products comprise MagnetOs Granules EU and MagnetOs Putty EU for the treatment of orthopedics, spinal, and dental problems; and MagnetOs Granules US and MagnetOs Putty US for the treatment of spinal fusion.
| Type | Public | |
| Founded | 2000 | |
| HQ | Schlieren, CH | Map |
| Website | kuros.ch |
Recent NewsAll News
- Kuros Biosciences Reports Results for the Full Year 2019
- Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North American Spine Society 34th Annual Meeting
- Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion
- Kuros Biosciences Reports Results for First Half 2019
Latest Updates
| Employees (est.) (Feb 2019) | 35 | (+25%) |
| Share Price (May 2020) | CHF2.1 | (-5%) |
Key People/Management at Kuros Biosciences
Joost de Bruijn
Chief Executive Officer, Director
Michael Grau
Chief Financial Officer
Alistair Irvine
Chief Business Officer
Pascal Longlade
Chief Medical Officer
Phillippe Saudan
Chief Development Officer
Scott Bruder
Non-Executive Director
Kuros Biosciences Office Locations
Kuros Biosciences has offices in Schlieren and Bilthoven
Schlieren, CH (HQ)
25 Wagistrasse
Bilthoven, NL
Professor Bronkhorstlaan 10, G 48
Kuros Biosciences Financials and Metrics
Kuros Biosciences Revenue
Market capitalization (27-Apr-2020) | 46.0m |
Closing stock price (27-Apr-2020) | 2.0 |
Kuros Biosciences's current market capitalization is CHF46 m.
Kuros Biosciences Online and Social Media Presence
Kuros Biosciences's Trends
Kuros Biosciences News and Updates
September 24, 2019
Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North American Spine Society 34th Annual Meeting
SCHLIEREN (ZURICH), Switzerland, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences, a leader in next generation bone graft technologies, today announces the full commercial launch of MagnetOs™ and the company’s first attendance as an exhibitor at NASS, the world’s largest spine meeting and exhi…
September 03, 2019
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion
SCHLIEREN (ZURICH), Switzerland, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences, a leader in next generation bone graft technologies, today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase 2a clinical t…
April 09, 2019
Kuros Biosciences Enters Convertible Bond Financing Agreement For Up To CHF 5 Million
SCHLIEREN (ZURICH), Switzerland, April 09, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN) today announced that it has entered into a convertible bond financing agreement with Nice & Green S.A. for up to a maximum of CHF 5 million.
Kuros Biosciences Frequently Asked Questions
When was Kuros Biosciences founded?
Kuros Biosciences was founded in 2000.
Who are Kuros Biosciences key executives?
Kuros Biosciences's key executives are Joost de Bruijn, Michael Grau and Alistair Irvine.
How many employees does Kuros Biosciences have?
Kuros Biosciences has 35 employees.
Who are Kuros Biosciences competitors?
Competitors of Kuros Biosciences include Sorrento Therapeutics, Pernix Therapeutics and Alnylam Pharmaceuticals.
Where is Kuros Biosciences headquarters?
Kuros Biosciences headquarters is located at 25 Wagistrasse, Schlieren.
Where are Kuros Biosciences offices?
Kuros Biosciences has offices in Schlieren and Bilthoven.
How many offices does Kuros Biosciences have?
Kuros Biosciences has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies